I am in at $2.35. - Oversold, RSI @ 21 - $9.5 USD financing just closed at $3.10 CDN with insiders/institutions buying ahead of COVID-19 treatment Phase 2 trial results - Will need to maintain $4+ stock price to stay listed on NASDAQ - Gaps above at 3.33 & 5.56 - Signs of bottoming out - 25M in cash; with Cannabis asset sale (~20M), the cash position will exceed market cap - Due for COVID-19 treatment Phase 2 trial results within a week or two
That stock is a dog that don't hunt. Good luck. Those guys are crooks running it.
wealth_bakery
⋅
@KidKrempa I hear you, however getting to FDA-approved Phase II Trial stage is no small feat and insiders/insitutions loaded up at big premium to sp. It multi-bagged in a single day on the last 3 material press releases. Given how oversold it is, I very much like the risk/reward here.